• Title/Summary/Keyword: passive hemagglutination

Search Result 36, Processing Time 0.025 seconds

Evaluation of Vi-Passive Hemagglutination, SD$^{(R)}$ Kit, and Widal Test for Serological Diagnosis of Typhoid Fever (장티푸스의 혈청학적 진단을 위한 Vi-수동혈구응집법, SD$^{(R)}$ Kit 및 Widal 시험에 대한 효용성 평가)

  • Kim, Sung-Hun;Kim, Shuk-Ho;Lee, Deog-Yong;Lee, Esther;Park, Mi-Sun;Lee, Bok-Kwon
    • Korean Journal of Microbiology
    • /
    • v.46 no.2
    • /
    • pp.219-222
    • /
    • 2010
  • In this study, we evaluated Vi-passive hemagglutination (Vi-PHA), SD Salmonella Typhi IgG/IgM ($SD^{(R)}$ kit) and Widal test for the rapid laboratory diagnosis of typhoid fever patients. A total of 36 serum samples from febrile patients in Korea from 2005 to 2006 were used. Among 36 patients, 27 were fever patients without typhoid, 9 were typhoid fever. Vi-PHA showed 8 positive results out of 9 typhoid fever patients (sensitivity 88.9%) and 1 positive and 26 negative results out of 27 febrile patients without typhoid (specificity 96.3%). The sensitivity and the specificity of $SD^{(R)}$ kit were 100% and 92.6%, respectively. However, the sensitivity and the specificity of Widal O & H tests were 88.9%, 100%, and 77.8%, 70.4%, respectively. Consequently, Widal H and $SD^{(R)}$ kit showed higher sensitivity and Vi-PHA showed higher specificity. To efficient diagnosis, Vi-PHA may be sufficient diagnosis method in acute cases and $SD^{(R)}$ kit and Widal test may be sufficient in sporadic area and high risk group.

Antigenicity of a Water Soluble Dimethyl Dimethoxy Biphenylate Derivative(DDB-S), a New Antihepatitis Agent (새로운 간염치료제인 수용성 DDB 유도체 (DDB-S)의 항원성 평가)

  • Han, Hyung-Mee;Kim, Jin-Ho;Choi, Kyoung-Baek;Kim, Hyung-Soo;Chung, Seung-Tae;Moon, Jeon-Ok;Lee, Chi-Ho;Kim, Joo-Il
    • Toxicological Research
    • /
    • v.14 no.3
    • /
    • pp.307-313
    • /
    • 1998
  • Dimethyl dimethoxy biphenylate (DDB) is an agent used to treat hepatits. DDB-S (DDB-soluble), a new DDB derivative, was synthsized to increase water solubility of the original DDB. In the present study, the antigenic potential of DDB-S was examined by active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA) and passive hemagglutination (PHA) tests. The experimental groups consist of a low dosage group, a high dosage group, he group emulsified with Freund's complete adjuvant (FCA, ASA test) or an alum (PCA and PHA tests) and the macromolecule conjugate group emulsified with FCA or an alum. In the ASA test, all experimental groups showed negative responses whereas the positive control group given ovalbumin plus FCA showed severe anaphylactic responses. In the heterologous PCA test using mice and rats, positive responses were not detected in any of the experimental groups. In the PHA test, all experimental groups showed negative responses whereas the positive control group given ovalbumin plus an alum showed 512~2048 PHA titers. These results demonstrated that DDB-S does not have any antigenic potential. These can be utilized as a part of preclinical data for the development of DDB-S as an intravenous injection.

  • PDF

A Study on the Positive Rates of HBsAg and Anti-HBs from Old People's Home and Casual Ward in Daegu, Korea

  • Shin, Hyun Gyu
    • Korean Journal of Clinical Laboratory Science
    • /
    • v.43 no.4
    • /
    • pp.145-149
    • /
    • 2011
  • Serum hepatitis is still recognized as a major public health problem in many countries. The most common etiologies are acute viral hepatitis A and B, and hepatitis B virus (HBV) was known as the pathogen of serum hepatitis. since the HBV causes chronic hepatitis. HBV infection is hyperendemic in Korea. It is known that 8% and 1% of the Korean population is chronic carriers of HBV. The total number of 487 serum specimen (old people's home 190, causal ward-Daegu hope village 297) were collected at the laboratory of Department of Clinical Pathology of Daegu medical center. The laboratory tested the specimen to detect for hepatitis B surface antigen (HBsAg) and anti-HBs using reverse passive hemag-glutination (RPHA) and passive hemagglutination (PHA) method between April, 2011 and June, 2011. In one-step test, HBsAg and anti-HBs of Humasis were used. The positive rate for HBsAg was 6.80% (33/487), and the rate in male was 6.93% (19/274) higher than that of female 6.57% (14/213). In the positive rate of HBsAg by age group, the highest positive rate group was in the group of 40-49 years in male (12.0%), and 50-59 years in female (17.65 %). The overall positive rate for anti-HBs was 42.70% (208/487), showing the higher positive rate of 43.80% in male (120/274) than that of 41.30% (88/213) in female. The highest positive rate of anti-HBs in age group was the 40-49 years group in male (52.00%) and the group of under 29 in female (66.67%).

  • PDF

Immunogenicity Study of Recombinant Human Basic Fibroblast Growth Factor

  • Kim, Dong-Hwan;Cho, Hyeon;Kang, Kyung-Koo;Ahn, Byoung-Ok;Kang, Soo-Hyung;Kim, Won-Bae
    • Biomolecules & Therapeutics
    • /
    • v.7 no.1
    • /
    • pp.14-21
    • /
    • 1999
  • The immunogenicity of the recombinant human basic fibroblast growth factor (rh-bFGF) was investigated by tests for active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA), passive hemagglutination (PHA) and guinea pig maximization test (GPMT) in mice or guinea pigs. Guinea pigs were sensitized with rh-bFGF ($100-1000\;\mu\textrm{g}/kg$) or rh-bFGF-CFA mixture ($1000\;\mu\textrm{g}/kg$). All animals sensitized with rh-bFGF alone or mixture with CFA showed symptoms of anaphylactic shock. IgE antibodies to rh-bFGF were detected in sera obtained from rh-bFGF and rh-bFGF-Alum ($1000\;\mu\textrm{g}/kg$) sensitized mice, indicating that rh-bFGF has immunogenicity eliciting potential. IgG and/or IgM antibodies to rh-bFGF were also detected in all the sera obtained from sensitized mice by PHA. In the GPMT for delayed type skin reaction, no skin reaction was observed in sensitized guinea pigs after intradermal injection and dermal application of 0.01% rh- bFGF. However, these positive reactions were consistent with the results of another rh-bFGF, showing that rh- bFGF is a heterogenous protein to rodents. Considering the fact that rh-bFGF is a genuine human protein of which structure is identical to the endogenous human bFGF, it is thought that rh-bFGF is rarely associated with immunological problems in clinical use.

  • PDF

Research of Experimental Kamidangkwieumja in Psoriasis (乾癬에 活用되는 加味當歸飮子에 對한 實驗的 硏究)

  • Lee, Keun-hak;Roh, Seok-seon
    • The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
    • /
    • v.12 no.1
    • /
    • pp.113-142
    • /
    • 1999
  • The purpose of this research was to investigate the effect of Kamidangkwieumja(KDEJ) water extract on the allergy reaction in mice. The results were obtained as follows: 1. The passive cutaneous anaphylaxis induced by egg albumin in fat was not affected. 2. The lethal anaphylaxis induced by platelet activating factor in mice. was inhibited. 3. The degranulation of peritoneal mast cells induced by compound 48/80 was not affected. 4. The acute hind paw edema was inhibited after 2hours later when it was induced by histamine. 5. The permeability of evans blue into peritoneal cavity induced by acetic acid was not affected. 6. Arthus reaction in mice was not affected. 7. The delayed type hypersensitivity induced by SRBC was inhibited. 8. The contact dermatitis induced by DNFB was not affected. 9. The hemagglutination titer induced by SRBC was inhibited. 10. The writhing syndrome induced by acetic acid was inhibited. 11. The population of heper T cells in mice thymus was enhanced. 12. The phagocytic activity of peritoneal macrophages was enhanced. 13. The production of nitric oxide from peritoneal macrophages was not affected. These results suggest that the anti-allergy effect of KDEJ is caused by steroidlike and enhanced immune action. The steroidlike action of KDEJ correspond with steroid-applying-method that frequently used in clinic, so it is used io treatment of psoriasis. The research on anti-allergy of KDEJ might has to be continued.

  • PDF

A Study on Antigenicity of Recombinant Human Interferon $\beta$ (LB00013) in Mice and Guinea Pigs

  • Park, Jong-Il;Jeong, Tae-Cheon;Cha, Shin-Woo;Shin, Ho-Chul;Han, Sang-Seop
    • Toxicological Research
    • /
    • v.12 no.1
    • /
    • pp.81-86
    • /
    • 1996
  • Antigenicity of recombinant human interferon $\beta$(LB00013), a newly developed drug for anti-cancer and anti-viral therapeutic use, was investigated in mice and guinea pigs. The following results were obtained: 1. Mice showed no production of antibodies against LB00013 sensitized with aluminum hydroxide gel (Alum) as an adjuvant, when judged by the heterologous passive cutaneous anaphylaxis (PCA) test in rats. Meanwhile, antibodies against ovalbumin (OVA) sensitized with Alum were clearly detected. 2. In guinea pigs, the sensitization of neither LB00013 only nor LB00013 with complete Freund's adjuvant (CFA) produced positive reactions in the homologous active systemic anaphylaxis (ASA) and the PCA tests. Meanwhile, the sensitization of OVA with CFA produced positive reactions in both PCA and ASA. 3. A LB00013-specific reaction was not observed in an indirect hemagglutination(IHA) assay using sera isolated from LB00013 sensitized mice. The present results suggested that LB00013 may have no antigenic potential in mice and guinea pigs.

  • PDF

Clarithromycin Therapy for Scrub Typus (쯔쯔가무시(Tsutusgamushi)병에서 Clarithromycin의 치료 효과)

  • Kim, Soon;Jung, Eun Mi;Moon, Kyung Hyun;Yoe, Sung Yeob;Eum, Soo Jung;Lee, Joo Hyung;Jo, Sung Rae;Ma, Sang Hyuk
    • Pediatric Infection and Vaccine
    • /
    • v.9 no.2
    • /
    • pp.175-181
    • /
    • 2002
  • Purpose : Scrub typhus(tsutsugamushi disease) is a febrile disease characterized by fever, rash, eschar, lymphadenopathy. Therapy with tetracycline(doxycycline) or chloramphenicol is currently recommended for the treatment for scrub typhus. But there are limitations in usage a tetracycline(doxycycline) for scrub typhus in the children. Recently, there was a report that azithromycin, a macrolide antibiotic was used for scrub typhus in pregnant woman successfully. So we evaluated the effectiveness of the Clarithromycin, other a macrolide antibiotic, for scrub typhus. Methods : Seven patients with scrub typhus at department of internal medicine and three patients with scrub typhus at department of pediatrics Masan Fatima Hospital were involved for this study. A serologic diagnosis for scrub typhus were performed by use of passive hemagglutination test. Clarithromycin(Abbott Laboratories, North Chicago, IL, USA) was administrated orally in a daily dose of 500 mg for adult patients and 15 mg/kg/bid/day for pediatric patients. Results : There were 7 cases of adult patients, varying from 28 to 76 years of age and 3 cases of pediatirc patients, varying from 4 to 7 years of age with scrub typhus. All of cases had fever, myalgia, headache, rash, eschar. Seven cases had positive passive hemagglutination test and eight cases had abnormal liver function. Mean duration for the removal of fever after medication was 1.3 day(1~2 days) and all cases were recovered without complications. Conclusion : Our results suggest that Clarithromycin therapy may be effective for scrub typhus.

  • PDF

A Research on the Positive Rate of HBsAg Among the Healthy Korean (한국(韓國)의 건강인(健康人)에서 간염(肝炎) B항원(抗原)(HBsAg) 양성율(陽性率)에 대한 조사연구(調査硏究))

  • Lee, Soo-Young;Kim, Kang-Sueck
    • The Journal of the Korean life insurance medical association
    • /
    • v.1 no.1
    • /
    • pp.133-139
    • /
    • 1984
  • In the 2,218 healthy cases-male 1,574 female 644-who were conducted serum examination from May 1st 1983 to November 1st 1983 by the medical selection of Dae Han Kyouk life insurance Co., the results which investigated the HBsAg by using the Reverse Passive Hemagglutination(RPHA) method are as follows; 1. The number of 167 from 2,218 cases proved to be positive, showing 7.52%, the number of 143 from 1,574 male positive, showing 9.08%, and the number 24 from 644 female positive, showing 3.73%. The positive rate of the male was indicated by 5.36% higher than that of the female as the former marked 2.4 times higher distribution than the latter. 2) The positive rate by the type of occupations appears as follows; The highest positive rate group is that of discharger from military service in 1983, the number of 70 from 736 persons marking 9.51% and the next is the merchant 8.79%(8/91), employee of a company markes 8.53%(44/516), high school boy 7.69%(19/247), house wife 5.71%(10/210), carrier woman 3.45%(10/290) and the group of the high school girl records the minimum rate of all, 3.13%(4/128). 3. The positive rate by the age group appears as follows; The highest rate group is that of 31 to 35 years, marking 9.80% positive rate, and the next is $26{\sim}30$(9.3%), $21{\sim}25$(8.01%), $41{\sim}45$(6.96%), $36{\sim}40$(6.9%), those below 20(5.99%), 46 to 50 years shows the minimum rate of all(2.94%) Among the male case, 26 to 30 years shows the highest positive rate by 10.59% and female, 31 to 35 years shows the highest rate by 7.89%. 4. The positive rate by the blood type represents as follows; Blood type A shows 7.30%, type B 7.17%, type O 6.11% and type AB indicates 5.88% in order.

  • PDF

A Study on Antigenicity of G009, a Polysaccharide Isolated from Gandoderma lucidum IY009 in Mice and Guinea pigs (영지의 단백다당체 G009의 마우스와 기니픽에 있어서의 항원성에 관한 연구)

  • Park, Jong-Il;Jeong, Taw-Cheon;Cha, Shin-Woo;Shin, Ho-Chul;Jeong, Hoon;Kim, Su-Ung;Han, Sang-Seop
    • Biomolecules & Therapeutics
    • /
    • v.4 no.1
    • /
    • pp.1-6
    • /
    • 1996
  • In the present study, the antigenic potential of G009, a polysaccharide isolated from Ganoderma lucidum IY009, was determined in BALB/C mice and Hartley guinea pigs. Antigenicity tests, including passive cutaneous anaphylaxis (PCA), active systemic anaphylaxis (ASA) and indirect hemagglutination test (IHA) were performed according to the established guidelines of National Institute of Safety Research. The results were as follows: 1. Mice showed no production of antibodies against G009 sensitized with an adjuvant, aluminum hydroxide gel (alum), when judged by the heterologous PCA test in rats. Meanwhile, antibodies against ovalbumin (OVA) sensitized with alum were clearly detected. 2. In the studies with guinea pigs, both the sensitization of G009 alone and of G009 with complete Freund's adjutant (CFA) did not produce positive reactions in homologous PCA. In the case of ASA, however, G009 alone and G009 with CFA produced positive reactions. 3. No G009 specific reaction was observed in an IHA assay using sera isolated from G009 sensitized mice. These findings suggest that G009 have no antigenicity potential in mice but may have weak antigenicity in guinea pjgs.

  • PDF

Immunogenicity and Safety of Vi Capsular Polysaccharide Typhoid Vaccine in Healthy Persons in Korea

  • Lim, Sang-Min;Jung, Hahn-Sun;Kim, Min-Ja;Park, Dae-Won;Kim, Woo-Joo;Cheong, Hee-Jin;Park, Seung-Chul;Lee, Kwang-Chul;Shin, Young-Kyoo;Tan, Hyun-Kwang;Kim, Sang-Lin;Sohn, Jang-Wook
    • Journal of Microbiology and Biotechnology
    • /
    • v.17 no.4
    • /
    • pp.611-615
    • /
    • 2007
  • The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were $5.87{\pm}1.34\;and\;142.59{\pm}2.39$ at one month after vaccination. For adults, the GMTs before and one month after vaccination were $5.58{\pm}1.28\;and\;58.56{\pm}3.67$, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.